SGLT2 inhibition in kidney disease: key lessons from EMPA-REG OUTCOME

10' education - July 11, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Christoph Wanner, MD - University of Würzburg, Germany - Online CME

Prof. Wanner summarizes the key lessons from the EMPA-REG OUTCOME trial in patients with pre-existing CKD.

Video navigation menu

EMPA-REG OUTCOME: eGFR over 3 years 02:32
New onset or worsening of nephropathy 04:20
Outcome in patients with pre-existing CKD (renal population) 08:28
New onset or worsening of nephropathy: subgroup analysis 10:06
Safety 12:30

Educational information

This lecture was part of a CME accredited symposium: Epigenetics in CKD & CVD: A potential breakthrough therapy? held at ERA-EDTA in Copenhagen, Denmark.

Faculty

Professor Christoph Wanner, MD - University of Würzburg, Germany

Disclosures

This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.

Funding

Funding for this educational program was provided by an unrestricted educational grant from Boehringer Ingelheim/Lilly.

View slides of prof. Wanner

Online-CME

This is available as accredited online CME for members. Click the button below to enroll:

Enroll

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.